Why is the stock market not yet? Sesex tumbles more than 800 points, handy under 24,650; 5 important factors behind the massacre

Indian benchmark – Indices dropped on Friday after US President Donald Trump had announced steep rates of the import of ‘brand and patented’ drugs with effect from 1 October 2025.

Sesex tumbled more than 800 points to act below the level of 80,400; In the meantime, the Nifty50 fell more than 250 points to slip under the 24,650 level.

Here are top factors behind the market trap:

1) Farma sector is bleeding at the rate of misery

The shares of Indian Pharma fell on Friday after investors responded to the relocation of US President Donald Trump to impose a 100% rate on ‘branded servants’.

Sectormeter Nifty Pharma refueled 590 points or 2.7% that hit the day of the day of 21,390.25. There were 17 losers in the 20-stock index, while only three managed to exchange the green. Laurus Labs, Biocon, Zydus Lifesciences and Natco Pharma were among the great losers and fell to 7%.

2) Global markets in red

Asian markets traded deep in the red on Friday, with wide sale over large indices. The Japanese Nikkei fell 0.9%, Hong Kong’s Hang Seng fell 1.4%and China’s Shanghai composite fell by 0.7%around 2:12 pm Ist.

3) FII sale

Markets are affected by a large sale trend by foreign institutional investors (FIIs). On Thursday they sold domestic shares worth RS 4,995.42 Crore, which used the flow from September to RS 13,450 Crore. In 2025, they have thrown out domestic shares worth RS 1,44.085 Crore so far.

4) Weakness in rupees

While the rupee managed to stay above the low point of 88,7975 against the US dollar, investors will follow the closure today. The Indian rupid is expected to remain under pressure in the light of current developments. The newest rate for the pharmaceutical sector and the H1-B visa decision came as a double blow to the Indian markets.

“It is still unclear how branded or patented pharmaceutical products will be defined, but our work assumption is that this will not include generic medicines and pharmaceuticals sent by India to the US,” Reuters reported, “said Michael Wan, Senior Caluta Analist at MUFGG.

The US is good for just over a third of the pharmaceutical exports of India, mainly consisting of cheaper generic versions of popular medicines. India’s American turnover rose by 20% on an annual basis to around $ 10.5 billion in tax 2025.

5) Bullion’s rising attraction

The loss on the Indian stock markets has been a blessing for the domestic precious metal markets, because investors are flooding for Gold and Silver’s Safe Haven Appeal. The domestic prices of gold and silver have been appreciated by more than 47% and 58% respectively in 2025 respectively.